Navigation Links
Independent publication supports the profile of CeNeS phase II,compound, CNS 5161

possibility. These properties of CNS 5161, together with its low liability to induce side-effects, are the scientific foundation for our clinical development programme of CNS 5161 as a novel treatment for the major neuropathic pain market. We plan to test CNS 5161 in further Phase II trials in cancer pain and neuropathic pain later this year."

*In vitro and in vivo characterization of [3H]CNS-5161. A use-dependent ligand for the N-methyl-d-aspartate receptor in rat brain. Biegon et al., Synapse, volume 61, pages 577-586, 2007.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About CNS 5161 A range of primary diseases or conditions such as diabetes, cancer, HIV/Aids and shingles, or surgical procedures such as limb amputation can result in nerve damage which leads to a sustained chronic pain. This neuropathic pain is difficult to treat as traditional analgesics do not provide adequate relief for many patients. Drug treatments for neuropathic pain represent a significant area of unmet medical need and a growing market opportunity that is currently valued at over $2 billion globally. Glutamate (particularly NMDA) receptors have been implicated in the induction and maintenance of neuropathic pain and NMDA antagonists may represent a class of drugs for effective relief of neuropathic pain. CNS 5161 is a blocker of the NMDA ion channel and has completed Phase I and more recently Phase IIa proof of c
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
8. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
11. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
Post Your Comments:
(Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
(Date:10/30/2014)... Oct. 30, 2014 Today Eli Lilly and ... its long-standing technology transfer program to increase the global ... 2003, the effort included Lilly donating manufacturing technology and ... China , India , ... Africa – all MDR-TB ,hot spots., It ...
(Date:10/27/2014)... , Oct. 27, 2014  Demonstrations by ... devices are being featured this week in ... Scientific Assembly where more than 7,000 emergency physicians ... and participating in educational courses. These ... drop of true-to-life emergency department environments, including three ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/30/2014)... 30, 2014 Victory Healthcare, a ... 2014 third quarter infection rates and patient satisfaction ... rates of only two percent or less, and ... exceeding 98 percent. , “We are delighted with ... rising satisfaction scores,” said Robert Helms, chairman and ...
(Date:10/30/2014)... who used stem cells to create miniature human stomachs ... new way to learn more about the development and ... pluripotent stem cells -- which can become any type ... functional miniature stomachs, to study infection by H. ... stomach cancer. The miniature stomachs offer many research ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Many U.S. ... campus, even though tanning increases the risk for ... among young adults, particularly white women, so colleges ... health, the researchers said. "Public health efforts ... population awareness of the harms that indoor tanning ...
(Date:10/30/2014)... -- A new vaccine that could help prevent some ... the U.S. Food and Drug Administration on Wednesday. ... of 10 and 25 from invasive meningococcal disease caused ... The bacteria can infect the bloodstream (sepsis) and the ... is a leading cause of bacterial meningitis, and infection ...
(Date:10/29/2014)... development of minimally and even non-invasive technologies is increasing ... instance, to carry out a range of operative procedures ... leaving only tiny scars as a result. Similar opportunities ... agents to patients – instead of using injections or ... possible to supply them via a plaster which continuously, ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... . , The PhD, defended by Ana ... Country, proposes a series of recommendations that contribute to ... treat terminal cancer patients. , Autonomy is the capacity ... knowledge about the causes of the illness, sufficient information ...
... Shared Health, Inc.,provider of secure health information ... Tennessee to provide its electronic health record,solutions ... health information,network called the Tennessee Information Network ... partnership with the State of Tennessee began ...
... The Providence Service,Corporation (Nasdaq: PRSC ) today announced ... fourth quarter and year ended December 31, 2007,on Wednesday, ... will hold a conference call at 11:00 a.m. EDT ... March 13, 2008 to discuss its,financial results and corporate ...
... Bowl champ O.J. Brigance,who recently confirmed a diagnosis ... The Robert Packard Center for ALS Research at ... the Center to fund,research to find a cure ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080303/NEM042 ), The ...
... Faculty of 1000 Medicine, researchers look at the way ... used by physicians in Quebec. , The authors ... that general practitioners diagnosed 79% of the 10,001 rheumatoid ... a rheumatologist. Half of these patients were seen in ...
... study has found that elevated liver enzymes discovered ... future mortality. The findings are in the March ... Wiley & Sons on behalf of the American ... The article is also available online at Wiley ...
Cached Medicine News:Health News:Factors that enhance autonomy of cancer patients 2Health News:Factors that enhance autonomy of cancer patients 3Health News:Shared Health Partners With State of Tennessee to Provide Electronic Health Information for Statewide Health Information Network 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:O.J. Brigance Named Honorary Chair of May 3 Race to Cure ALS, Confirms His Diagnosis by The Robert Packard Center for ALS Research at Johns Hopkins 2Health News:Elevated liver enzymes associated with higher future mortality 2
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... fit for all astigmatic patients. Ideal ... who require excellent visual acuity and ... of disposable lenses; astigmatic spectacle wearers ... lenses; and spherically masked astigmatic patients ...
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
... Vitrasert implant is a device ... with Aids-related Cytomegalovirus (CMV) Retinitis. This ... CMV when compared with conventional intravenous ... embedded in a polymer-based system that ...
Medicine Products: